Real-world effectiveness of SGLT2 inhibitors in adults aged 75 years or older: a target trial emulation
{{output}}
Background: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) improve cardiovascular and renal outcomes, but evidence in adults aged ≥75 years remains limited, particularly compared with dipeptidyl peptidase-4 inhibitors (DPP-4... ...
